Panitumumab (powder) (Synonyms: ABX-EGF (powder))

Cat. No.: HY-P99041B: Data Sheet
FAQs
Technical Support

Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer.

For research use only. We do not sell to patients.

CAS No. : 339177-26-3

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Panitumumab (powder):

Panitumumab

Other Forms of Panitumumab (powder):

Panitumumab In-stock

2 Publications Citing Use of MCE Panitumumab (powder)

: Panitumumab (powder) purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]; HeLa cells were pretreated with 100 nM cetuximab (Cmab) or 30 nM panitumumab (Pmab) for 10 min and then stimulated with 20 ng/mL TNF-α for 15 or 60 min. The expression of the indicated proteins was detected by immunoblotting.

: Panitumumab (powder) purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]; Panitumumab (100 nM, 25 min) was internalized upon stimulation with TNF-α (20 ng/mL, 15 min) in HeLa cells.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Human IgG2 kappa

Recommend Isotype Controls

Human IgG2 kappa, Isotype Control

Species Reactivity

Human

In Vitro

Panitumumab (2 nM-2 μM, 3 h) (powder) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells^[3].
Panitumumab (0-200 μg/mL, 48 h) (powder)inhibits the proliferation of DLD-1 cells^[4].
Panitumumab (80 μg/mL, 24 h) (powder) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:	EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
Concentration:	2, 20, 200, 2000 nM
Incubation Time:	3 h
Result:	Inhibited ligand-induced autophosphorylation of EGFR.

In Vivo

Panitumumab (25-500 μg per mouse, i.p., twice a week) (powder) inhibits tumor growth in the xenograft models of NCI-H1975 and NCI-H1650 in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCI-H1975 and NCI-H1650 xenografts^[3]
Dosage:	25, 100, or 500 μg/mouse
Administration:	Intraperitoneal injection (i.p.), twice a week
Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.

Clinical Trial

Gene ID

1956 [NCBI]

Accession

P00533

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

144.32 kDa

CAS No.

339177-26-3

SMILES

[Panitumumab (powder)]

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. PMID: 20044619.. . . [Content Brief]

[2]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9. [Content Brief]

[3]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51. [Content Brief]

[4]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546. [Content Brief]

[5]. Efstathia Giannopoulou, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82.

Panitumumab (powder) Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Panitumumab (powder)339177-26-3ABX-EGF (powder)EGFREpidermal growth factor receptorErbB-1HER1human IgG2anti-EGFRmonoclonal antibodyanti-tumorNCI-H1975NCI-H1650CHODLD-1Caco-2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *